Lipired 200mg Capsule 1 Strip

✔️ Uses of Lipired 200

• High triglyceride levels (Hypertriglyceridemia).
• Elevated cholesterol levels (Hypercholesterolemia).
• Mixed lipid disorders (Mixed Dyslipidemia).

✔️ Fenofibrate may interact with several medications:

• Bile acid sequestrants (e.g., Cholestyramine): May reduce fenofibrate absorption when taken together.
• Cyclosporine: May increase the risk of kidney toxicity.
• Statins (e.g., Simvastatin): May increase the risk of muscle-related adverse effects, including myopathy and rhabdomyolysis.
• Oral anticoagulants: May enhance their anticoagulant effects and increase the risk of bleeding. Close monitoring and possible dosage adjustment may be necessary.

✔️ Adverse Effects

Common adverse reactions (approximately 1–10%):

• Abdominal pain.
• Back pain.
• Elevated AST and ALT liver enzymes.
• Headache.
• Increased creatine phosphokinase (CPK).
• Nausea.
• Constipation.

Potentially serious adverse reactions:

• Hepatitis.
• Cholecystitis.

✔️ Words of Advice

• Take the medication with food, following your prescribed instructions.
• Avoid excessive alcohol consumption during treatment.
• Your doctor may recommend liver function tests before and during treatment.
• Inform your doctor if you experience unusual tiredness, loss of appetite, yellowing of the skin or eyes, or dark-colored urine, as these may indicate liver problems.
• Report unexplained muscle pain, tenderness, cramps, or weakness, particularly if accompanied by fever.
• Do not stop taking the medication without medical advice.
• Regularly monitor your cholesterol and triglyceride levels.
• Maintain a healthy diet and exercise routine throughout treatment.

✔️ Lipired 200 should not be used in patients with:

• Known hypersensitivity to fenofibrate or its ingredients.
• Severe liver or kidney impairment.
• Persistent unexplained abnormalities in liver function.
• Pre-existing gallbladder disease.
• Certain forms of primary biliary disease.
• Pregnancy or breastfeeding, unless specifically evaluated and advised by a specialist.

✔️ Pregnancy & Lactation

Pregnancy:

Available clinical information regarding fenofibrate use during pregnancy is limited. Animal studies have not demonstrated significant fetal toxicity at certain therapeutic doses; however, adverse reproductive effects have been observed at higher exposures. Therefore, fenofibrate should generally be avoided during pregnancy unless a specialist determines that the potential benefits outweigh the possible risks.

Lactation:

There is insufficient information regarding the presence of fenofibrate in human breast milk and its potential effects on nursing infants. Because of the possibility of adverse effects on infant lipid metabolism, breastfeeding is generally not recommended during treatment and for five days following the final dose, according to relevant product labeling.

✔️ Dosage & Administration of fenofibrate

Adult Dosage:

For fenofibrate formulations, the recommended dosage varies according to the formulation, strength, and the patient's clinical condition.

• Tablets: Dosage may range from 40–160 mg once daily, depending on the formulation.
• Capsules: A 200 mg formulation may be prescribed once daily.

Dosage adjustments may be necessary in patients with impaired kidney function. Severe hepatic or renal impairment may contraindicate its use.

Pediatric Dosage:

The safety and effectiveness of fenofibrate in children have not been adequately established.

Renal Dosage:

Patients with mild to moderate renal impairment may require a reduced starting dose and careful monitoring. Use is generally contraindicated in severe renal impairment.

✔️ Safety

• Use cautiously in patients with existing liver or kidney disorders.
• Liver function tests and other relevant laboratory parameters should be monitored periodically.
• Fenofibrate may increase the risk of gallstone formation and pancreatitis.
• Muscle-related complications, including myopathy and rhabdomyolysis, may occur, particularly when combined with statins.
• Treatment should be reassessed if an adequate therapeutic response is not achieved after an appropriate treatment period at the maximum tolerated dose.
• Breastfeeding is generally not recommended during fenofibrate treatment.

✔️ Storage

Store in a dry, cool place